Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and lowers the price target from $37 to $27.
Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and lowers the price target from $37 to $27.